NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:NMR - US65535H2085 - ADR
7.58 USD
-0.06 (-0.79%)
We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 237 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
NMR had positive earnings in each of the past 5 years.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of 0.61%, NMR is not doing good in the industry: 69.62% of the companies in the same industry are doing better.
With a decent Return On Equity value of 10.62%, NMR is doing good in the industry, outperforming 60.76% of the companies in the same industry.
The Return On Invested Capital of NMR (0.66%) is worse than 70.04% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 6.96%.
The last Return On Invested Capital (0.66%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROIC | 0.66% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
NMR has a Profit Margin of 8.05%. This is in the lower half of the industry: NMR underperforms 63.71% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
NMR has a Operating Margin of 11.60%. This is in the lower half of the industry: NMR underperforms 65.82% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
With a Gross Margin value of 43.38%, NMR perfoms like the industry average, outperforming 48.95% of the companies in the same industry.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
NMR has less shares outstanding than it did 5 years ago.
NMR has a better debt/assets ratio than last year.
2.2 Solvency
NMR has an Altman-Z score of -0.20. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.20, NMR is doing worse than 78.48% of the companies in the same industry.
A Debt/Equity ratio of 10.65 is on the high side and indicates that NMR has dependencies on debt financing.
NMR has a worse Debt to Equity ratio (10.65) than 89.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.2 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.28. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a Current ratio of 0.28. This is amonst the worse of the industry: NMR underperforms 82.70% of its industry peers.
A Quick Ratio of 0.28 indicates that NMR may have some problems paying its short term obligations.
With a Quick ratio value of 0.28, NMR is not doing good in the industry: 82.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.52%, which is quite impressive.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
Looking at the last year, NMR shows a decrease in Revenue. The Revenue has decreased by -2.45% in the last year.
NMR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
3.2 Future
The Earnings Per Share is expected to grow by 2.33% on average over the next years.
The Revenue is expected to decrease by -6.12% on average over the next years.
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.13, which indicates a very decent valuation of NMR.
NMR's Price/Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 75.95% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, NMR is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.89, the valuation of NMR can be described as very reasonable.
NMR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 69.62% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of NMR to the average of the S&P500 Index (36.59), we can say NMR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.13 | ||
| Fwd PE | 9.89 |
4.2 Price Multiples
70.04% of the companies in the same industry are more expensive than NMR, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.26 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.4
PEG (5Y)0.83
EPS Next 2Y1.02%
EPS Next 3Y2.33%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 4.54%, which is a nice return.
NMR's Dividend Yield is comparable with the industry average which is at 8.60.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.54% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
18.37% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP18.37%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
NYSE:NMR (11/28/2025, 7:51:03 PM)
7.58
-0.06 (-0.79%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners41.49%
Inst Owner Change1.65%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.24B
Revenue(TTM)4.60T
Net Income(TTM)370.05B
Analysts73.33
Price Target7.69 (1.45%)
Short Float %0.05%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.54% |
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP18.37%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.49%
PT rev (3m)9.11%
EPS NQ rev (1m)-0.93%
EPS NQ rev (3m)1.67%
EPS NY rev (1m)7.4%
EPS NY rev (3m)6.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.51%
Revenue NY rev (3m)1.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.13 | ||
| Fwd PE | 9.89 | ||
| P/S | 0.76 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1 | ||
| P/tB | 1 | ||
| EV/EBITDA | 20.26 |
EPS(TTM)0.83
EY10.95%
EPS(NY)0.77
Fwd EY10.11%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS10.02
BVpS7.6
TBVpS7.6
PEG (NY)1.4
PEG (5Y)0.83
Graham Number11.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROCE | 1.62% | ||
| ROIC | 0.66% | ||
| ROICexc | 0.74% | ||
| ROICexgc | 0.76% | ||
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-ScoreN/A
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 62.4 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z | -0.2 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
EPS Next Y6.54%
EPS Next 2Y1.02%
EPS Next 3Y2.33%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
Revenue Next Year-18.6%
Revenue Next 2Y-9.83%
Revenue Next 3Y-6.12%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year24150%
EBIT Next 3Y528.12%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A
NOMURA HOLDINGS INC-SPON ADR / NMR FAQ
Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a fundamental rating of 3 / 10 to NMR.
Can you provide the valuation status for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.
What is the profitability of NMR stock?
NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.
How financially healthy is NOMURA HOLDINGS INC-SPON ADR?
The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.
What is the expected EPS growth for NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 6.54% in the next year.